A United States advisory group is currently assessing whether seven specific injectable peptides-BPC-157, emideltide (DSIP), epitalon, KPV, MOTS-c, semax, and TB-500-should be added to the list of bulk drug components permitted in compounded medications.Compounding pharmacies are still prohibited from preparing these peptides, but rising gray market trade and political momentum for expanded access have amplified...
